Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Little known about the impacts of cancer on the Australian workforce

Thirty seven thousand Australians aged 20-64 years of age were diagnosed with cancer in 2001 yet surprisingly little is known about the impacts of cancer on the Australian workforce.

8 Aug 2006

New blood test picks up early breast cancer

A new blood test has been developed by an international team of scientists which can detect the very early stage of breast cancer.

7 Aug 2006

BRIT1 gene plays a pivotal role in DNA damage detection and repair

A single gene plays a pivotal role launching two DNA damage detection and repair pathways in the human genome, suggesting that it functions as a previously unidentified tumor suppressor gene.

3 Aug 2006

Trial of Topotecan following Carboplatin and Paclitaxel in treatment of ovarian cancer

The drug topotecan does not increase survival for ovarian cancer patients when used with standard chemotherapy in first-line treatment and is not recommended for future use.

2 Aug 2006

Link between psychological stress and ovarian tumor growth

When mice with ovarian cancer are stressed, their tumors grow and spread more quickly, but that effect can be blocked using a medication commonly prescribed for heart disease.

24 Jul 2006

Researchers identify potential ovarian cancer stem cells

Massachusetts General Hospital (MGH) researchers have identified potential ovarian cancer stem cells, which may be behind the difficulty of treating these tumors with standard chemotherapy.

21 Jul 2006

FDA gives the green light for Gemzar to treat recurrent ovarian cancer

Drug company Eli Lilly has been given approval by the U.S. Food and Drug Administration (FDA) for its drug Gemzar to be used by women living with recurrent ovarian cancer.

18 Jul 2006

FDA approval for Gemzar for ovarian cancer

Eli Lilly and Company announced that the United States Food and Drug Administration (FDA) has approved Gemzar (gemcitabine HCl) for use in the treatment of women living with recurrent ovarian cancer.

18 Jul 2006

Women with mutations in BRCA1 or BRCA2 genes can reduce cancer risk by having ovaries removed

Women with mutations in the BRCA1 or BRCA2 genes can significantly reduce their risk of certain types of cancer by having their ovaries removed, according to a study in the July 12 issue of Journal of the American Medical Association.

12 Jul 2006

Two year wait for breast cancer test results drives women to consider radical surgery

Women in the UK being put under added stress because they are experiencing delays of two years or more for test results to see if they carry a gene associated with an increased likelihood of breast cancer.

20 Jun 2006

First drug treatment for late-stage cervical cancer approved

FDA has approved a combination of Hycamtin (topotecan hydrochloride) and cisplatin for use as the first drug treatment for women with late-stage cancer of the cervix.

18 Jun 2006

Reovirus could be used to treat many forms of advanced cancer

An experimental drug called Reolysin may give hope to patients suffering from advanced cancers, according to research presented at this year's meeting of the American Society of Clinical Oncology (ASCO).

8 Jun 2006

Black women twice as likely to get aggressive breast cancer

New research has found that African-American women who contract breast cancer before reaching menopause are more than twice as likely as white women to have an aggressive, deadlier form of the disease.

8 Jun 2006

Black women twice as likely to get aggressive breast cancer

7 Jun 2006

Prophylactic surgery reduces the incidence of ovarian and related cancers

A new multicenter study is the first to suggest that the prophylactic removal of the ovaries and fallopian tubes may provide a different benefit for women who carry a genetic mutation in the BRCA2 gene than for those who have a BRCA1 genetic mutation.

7 Jun 2006

Hormonal treatments reduce risk of cancer returning

Women diagnosed with breast cancer who carry a certain genetic mutation can have breast-sparing surgery but should consider hormonal treatments to reduce their risk of cancer returning.

6 Jun 2006

New data show Enzastaurin's activity across multiple cancer cell lines

Eli Lilly and Company's enzastaurin, an investigational, multi-targeted therapy that is currently the focus of two global Phase III clinical trials, one for the treatment of glioblastoma and one in non-Hodgkin's lymphoma

5 Jun 2006

Team effort to beat ovarian cancer

Canadian researchers are embarking on a project to develop new ways to detect ovarian cancer earlier, when it is treatable.

30 May 2006

Plasminogen activator inhibitor type 2 may play role in infection and dry eye

Plasminogen Activator Inhibitor Type 2 (PAI-2), a protein found in various cell types including the skin, has been discovered in the tissue covering the eye and may have future clinical implications in various pathologies of the ocular surface such as eye infection or dry eye.

17 May 2006

Extension of embryo screening will help reduce serious illness

A fertility watchdog in Britain, the Human Fertilisation and Embryology Authority (HFEA), has given approval for the extension of embryo screening to cover a wider range of mutated genes, in the main those which raise the risk of cancer in later life.

11 May 2006